TP53 and cancer: Interestingly, in a recent study mutant p53 was shown to mediate the repression of the NRF2 target gene SLC7A11 and a concomitant use of APR-246 with a glutathione synthesis inhibitor was revealed as an approach to eliminate cancer cells with mutant p53 [38].